secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2022-02-24T23:59:59+00:00
Accession:  0000950170-22-001973
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics reports FY2021 net loss of $363.9M; cash $958M into 2025
---------------------------------------------------------------------------

- Q4 net loss $67.5M vs net income $35.3M in Q4 2020; full-year net loss $363.9M ($3.82 loss per share).
- Cash, cash equivalents and investments $958.1M at Dec 31 2021, expected to fund operations into at least 2025.
- R&D expenses $172.7M for FY2021 (up from $99.9M in FY2020), driven by clinical trial and employee costs.
- Announced interim data for RLY-4008 (FGFR2 inhibitor) showing tumor shrinkage in all six treatment-naïve FGFR2 fusion+ cholangiocarcinoma patients.
- Dosed first patient in RLY-2608 (pan-mutant PI3Kα inhibitor) first-in-human trial; FDA granted orphan drug designation for RLY-4008 in cholangiocarcinoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017022001973/0000950170-22-001973-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017022001973/rlay-20220224.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-001973

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer